CVS Health Downgraded to Hold Despite Strong Q1 Results

Key Facts

In a move reflecting analyst divergence on CVS Health, Wall Street Zen downgraded the stock from Buy to Hold, according to market reports. The downgrade comes despite the company reporting strong Q1 results that beat earnings and revenue expectations. Wall Street Zen did not specify a reason for the downgrade.

Despite this downgrade, the consensus remains a Moderate Buy with an average price target of $101.28, per market data. CVS closed at $104.34 on June 26, recovering from an intraday low of $103.55. Other analysts have raised their price targets following the strong Q1 results, adding to uncertainty around the stock's direction.

Looking ahead, investors will focus on CVS Health's ability to sustain growth momentum amid competitive pressures in the healthcare sector. At current closing levels, support sits at $103.55 and resistance at $106.15. No immediate economic events on the calendar directly impact the stock, but upcoming sector earnings releases may provide new catalysts.